Xcelerate RARE: A Rare Disease Open Science Data Challenge
Learn More Getting data to the best people The Xcelerate RARE: A Rare Disease Open Science Data Challenge is bringing together researchers and
COugh Diagnostic Algorithm for Tuberculosis (CODA TB) DREAM Challenge
Learn More Tuberculosis (TB), a communicable disease caused by Mycobacterium tuberculosis, is a major cause of ill health and one of
Heart Failure Prediction: Microbiome
Learn More Cardiovascular diseases are the leading cause of death both in men and women worldwide. Heart failure (HF) is the
BraTS Continuous Evaluation
Learn More Brain tumors are among the deadliest types of cancer. Specifically, glioblastoma, and diffuse astrocytic glioma with molecular features of
Preterm Birth Prediction – Microbiome
Learn More Goal To develop predictive models for risk of preterm birth in pregnant individuals based on vaginal microbiome data. There
scRNA-seq and scATAC-seq Data Analysis
Learn More Understanding transcription signals at the individual cell resolution is fundamental to our understanding of more complex biological systems such
Predicting Gene Expression Using Millions of Random Promoter Sequences
Learn More Decoding how gene expression is regulated is critical to understanding disease. Regulatory DNA is decoded by the cell in
Crowd-Sourcing and Open Science
The DREAM Directors published a post on the FEBS Network headlined "Can crowd-sourcing help advance open science?" The article outlines some benefits
Anti-PD1 Response Prediction Dream Challenge
LEARN MORE While durable responses and prolonged survival have been demonstrated in some lung cancer patients treated with immuno-oncology (I-O) anti-PD-1
Winners of the $25,000 BEAT-PD DREAM Challenge Announced
NEW YORK (June 17, 2020) – The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Sage Bionetworks announce the winners of
COVID-19 EHR DREAM Challenge
LEARN MORE The rapid rise of COVID-19 has challenged healthcare globally. Due to the importance and emergent need for better understanding
CTD2 Chemosensitivity DREAM Challenge
Learn More The Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves
Subscribe to our Newsletter